News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Biotage AB: Interim Report January - March 2012
April 26, 2012
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
UPPSALA, Sweden--(BUSINESS WIRE)--Regulatory News: Biotage (STO:BIOTA): First quarter 2012 · Group net sales increased by 12 percent to 119.6 MSEK (107.2). At comparable exchange rates sales increased by 8 percent.
Twitter
LinkedIn
Facebook
Email
Print
Europe
MORE ON THIS TOPIC
Business
US biotechs take lion’s share of $54.5B VC money raised since 2025
October 26, 2026
·
1 min read
·
Gabrielle Masson
Policy
Roche flags ‘final opportunity’ for Germany to reestablish as a reliable investment location
October 23, 2026
·
2 min read
·
Nick Paul Taylor
Manufacturing
Sanofi breaks ground on insulin plant after securing German government support
October 19, 2026
·
2 min read
·
Nick Paul Taylor
cancer
Merck/Moderna, Summit/Akeso and ADCs to headline ESMO 2026
October 19, 2026
·
8 min read
·
Tristan Manalac
